EMBCEmbecta Corp. Common Stock
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringe…
Industry Peers
Medical Instruments & Supplies| Headline | Source | Time |
|---|---|---|
Older | ||
 Embecta (EMBC) Q3 2026 Earnings Call Transcript Revenue fell 8.1% year-over-year, but margin guidance rose for fiscal 2026. | ||
 Embecta Corp. Q3 2026 Earnings Call Summary Moby summary of Embecta Corp.'s Q3 2026 earnings call | ||
Embecta Corp (EMBC) (Q3 2026) Earnings Call Highlights: Strong Sequential Recovery and Raised ... Embecta Corp (EMBC) beats expectations with a $50 million sequential revenue jump, raises adjusted EPS guidance, and advances its Owen Mumford integration despite persistent U.S. market pressures. | ||
 Embecta Q3 Earnings Call Highlights Embecta (NASDAQ:EMBC) reported fiscal third-quarter 2026 revenue of approximately $272 million, down 8.1% from the prior-year period on a reported basis and down 8.9% on an adjusted constant-currency basis. The company said results improved sequentially from the fiscal second quarter, with revenue r | ||
 Embecta (EMBC) Stock Fair Value Moves Lower As Analysts Reset Medtech Expectations Embecta is in focus after one fair value estimate was reset from US$15.00 to US$4.00, which highlights how much some analysts have reworked their view of what the stock might be worth under updated assumptions. That shift sits alongside commentary pointing to a tougher setup for medtech valuations, higher inflation and capital flowing toward data center stocks, all of which are shaping how investors think about Embecta today. As you read on, you will see what is driving this evolving... | ||